-+ 0.00%
-+ 0.00%
-+ 0.00%

RPT-KEYTRUDA® (PEMBROLIZUMAB) PLUS TRODELVY® (SACITUZUMAB GOVITECAN-HZIY) REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 35% VERSUS KEYTRUDA PLUS CHEMOTHERAPY IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Reuters·05/31/2025 12:00:00

Please log in to view news